Syntara Limited Showcases at Investor Webinar
Pharmaxis Ltd (AU:SNT) has released an update. Clinical stage drug developer Syntara Limited announces its participation in the ShareCafe Small Cap...
Source: biztoc.com
📰 Pharmaxis Ltd News
Pharmaxis Ltd News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Pharmaxis Ltd. Real-time updates on events, politics, business and more.
Contrasting ProMetic Life Sciences (OTCMKTS:PFSCF) & Pharmaxis (OTCMKTS:PXSLY)
ProMetic Life Sciences (OTCMKTS:PFSCF – Get Free Report) and Pharmaxis (OTCMKTS:PXSLY – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, analyst recommendations and risk. Profitability This table compares ProMetic Life Sciences […]
Frenchs Forest New South Wales Pharmaxis Ltd Prometic Life Sciences Prometic Life Sciences Inc Drug Development
Source: dailypolitical.com
2023 Inhalers Pipeline Research Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies
/PRNewswire/ -- The "Inhalers Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update"...
South Australia United Kingdom New South Wales Laura Wood Eli Lilly Pure Scientific Technologies Inc
Source: prnewswire.com
Syntara doses first patient in bone cancer Phase 2 trial assessing SNT-5505 in combination with ruxolitinib
Syntara Ltd (ASX:SNT, OTC:PMXSF), formerly Pharmaxis Ltd, has dosed the first patient in a phase two clinical trial assessing its pan-LOX inhibitor SNT-5505...
Source: proactiveinvestors.com
FIVE at FIVE AU: Fed widely expected to relax monetary policy as ASX rises
The ASX 200 was up today, gaining 23.80 points or 0.33% to 7,259.10 and setting a new 50-day high. Over the last five days, the index has gained 1.24% and...
Source: proactiveinvestors.com.au
Syntara bolsters financial position with R&D tax incentive
Syntara Ltd, formerly Pharmaxis Ltd (ASX:PXS, OTC:PMXSF), a clinical-stage drug development firm specialising in blood-related cancers, has received a...
Fiona Wood Gary Phillips Syntara Ltd University Of Western Australia Pharmaxis Ltd Paddington Street Finance
Source: proactiveinvestors.com.au
FIVE at FIVE AU: RBA leaves cash rate on hold
The ASX is down today. The S&P/ASX200 dropped 68.80 points or 0.97% to 7,055.90 after setting a new 50-day high. Over the last five days, the index has...
Source: proactiveinvestors.com.au
Fight against cancer an enduring investment motivation in September quarter despite markets
Cancer remains one of the most pressing public health challenges worldwide, affecting millions of lives and compounding economic burdens along the way. ...
Source: proactiveinvestors.com.au
Global Inhalable Drugs Industry Trends and Competitive
Dublin, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The
Source: globenewswire.com